Check-Cap Overview
Check-Cap is a clinical-stage medical diagnostics company aiming to redefine colorectal cancer (CRC) screening through the introduction of C-Scan, a patient-friendly, preparation-free screening test that enables early intervention and cancer prevention by detecting polyps before they may develop into colorectal cancer. The company’s capsule-based screening technology is designed to significantly increase screening adherence worldwide, helping millions of people to stay healthy through preventive CRC screening. C-Scan uses an ultra-low dose X-ray capsule; an integrated positioning, control, and recording system; and proprietary software to generate a 3D map of the inner lining of the colon as the capsule travels naturally along the gastrointestinal tract. C-Scan is noninvasive and requires no sedation or bowel preparation, allowing patients to continue their daily routine without interruption. C-Scan is not intended to replace colonoscopies, and a positive C-Scan result should be followed by colonoscopy. In March 2021, the FDA approved Check-Cap’s investigational device exemption application, permitting it to begin a pivotal study of C-Scan in the United States.
Cumulative Funding Raised Over Time ($)
$4.0MApr 2020
$8.5MApr 2020
$14.4MAug 2016
$19.1MDec 2019
$26.6MFeb 2019
$26.9MJan 2022
$62.0MJun 2021
$71.8MMar 2011
$81.8MMar 2022
$84.5MMay 2017
$87.5MMay 2020
$90.0MNov 2017
$102.0MOct 2014
Latest News
growth-positive
MBody AI and Check-Cap Enter into Definitive Merger Agreement
Check-Cap Ltd. and MBody AI have announced a definitive merger agreement to create a combined company focused on embodied AI for the autonomous workforce. The merger, pending approval from Check-Cap shareholders, aims to leverage MBody AIs expertise in AI to expand into various industries such as hospitality, warehousing, and healthcare. The combined company will retain Check-Caps legacy assets, including patents and proprietary medical equipment, and will be renamed MBody AI Ltd. The merger is seen as a strategic move to enter a high-growth industry and capitalize on the expanding embodied AI market.
Acquired-by
growth-negative
Check-Cap claims BMO’s Chris Taves Illegally Attacks Israeli NASDAQ-Listed Company During Wartime
Check-Cap Ltd., a clinical-stage medical diagnostics company, has publicly condemned MediPharm Labs Corp. and its Chairman, Chris Taves, for issuing false and defamatory statements about Check-Cap. The company accuses Taves of exploiting his position at BMO Capital Markets to manipulate Check-Caps stock price by spreading misleading information during a sensitive time for Israeli companies. Check-Cap demands a retraction and apology from MediPharm Labs and Taves, asserting that their actions violate U.S. securities laws. Check-Cap is committed to defending its reputation and rights against these unethical attacks.
growth-negative
Apollo Technology Capital Corporation Poses Questions That MediPharm Shareholders Should Ask on Management's Conference Call with Shareholders
MediPharm Labs Corp. is facing significant challenges, with its stock value having plummeted by 99%, costing shareholders nearly $1 billion. Apollo Capital, a major shareholder, is pushing for changes in the companys board by nominating six new directors. The management team, led by CEO David Pidduck, has been criticized for poor operational strategies, lack of transparency, and excessive compensation despite the companys poor performance. The upcoming 2025 Annual Meeting on June 16 will be crucial as shareholders are urged to vote for a change in leadership. The company is also dealing with financial instability and accusations of misleading accounting practices.
Management Changes
growth-negative
Apollo Technology Capital Corporation to Nominate Six Highly Qualified Directors to MediPharm Labs' Board of Directors Following Years of Shareholder Value Destruction
Apollo Technology Capital Corporation, a significant shareholder of MediPharm Labs Corp., has filed a dissident information proxy circular to nominate six new directors to MediPharms Board. Apollo criticizes the current Board for the companys poor performance, reckless acquisitions, and excessive compensation, which have led to a significant decline in shareholder value. Apollos nominees bring extensive experience in turnaround strategies and the cannabis industry, aiming to restore value for shareholders. The Annual Meeting to vote on these changes is scheduled for June 10, 2025.
Management Changes
growth-negative
Check-Cap Leads 3 US Penny Stocks To Monitor
Check-Cap Ltd. is a clinical-stage medical diagnostics company focused on developing a capsule-based screening technology for colon diagnostics. Despite being pre-revenue and having a small market cap of $4.53 million, the company maintains financial stability with no debt and a sufficient cash runway. Recent management changes include David Lontini taking an active role as Chairman. The company is in the clinical trial stage and has not faced significant shareholder dilution. The article highlights the potential of penny stocks like Check-Cap in a market downturn, despite their inherent risks.
Product StageManagement Changes
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $134.22M |
| Last funding | $10M |
| Stage | Public |
| Rounds | 15 |
| Investors | 6 |
Team Members
6
Employees: 11-50
Web & Social Links
| Website | check-cap.com |
| Careers | Careers page |
Locations
Abba Hushi Boulevard 29, Isfiya, Israel
Photos & Videos
4 item(s)
Check-Cap Business
Business models
B2B
Product stage
Clinical Trial
Employees
11-50
Sector
Health Tech & Life SciencesDigital HealthcareDigital Medical DiagnosticsMedical DevicesDiagnostics DevicesTarget Customer
Healthcare & Life SciencesHealthcarePatientsProvidersCore Technology
Simulation & ImagingPlatforms & InterfacesSoftwareArtificial IntelligenceDeep LearningTags (18)
detectionx-raycancermedical-devices3d-technologycolonoscopyscreeningdiagnosticsgastroenterologynon-invasiveimagingdoctorshospitalsmedical-image-analysissoftware-platformdigital-healthcaremedical-technologiespatientsGeographic Markets
United StatesIsraelCheck-Cap Financials
$134.22M
Total funding
Undisclosed
Capital raised
$10M
Last funding
Public
Funding stage
15
Total rounds
6
Investors
Cumulative Funding Raised Over Time ($)
$4.0MApr 2020
$8.5MApr 2020
$14.4MAug 2016
$19.1MDec 2019
$26.6MFeb 2019
$26.9MJan 2022
$62.0MJun 2021
$71.8MMar 2011
$81.8MMar 2022
$84.5MMay 2017
$87.5MMay 2020
$90.0MNov 2017
$102.0MOct 2014
Private Equity Funding
PIPE
Mar 2022
$10M
Undisclosed Investor(s)
PIPE
Jan 2022
$300K
Intempo Ventures
PIPE
Jun 2021
$35M
Undisclosed Investor(s)
PIPE
May 2020
$3M
Undisclosed Investor(s)
PIPE
Apr 2020
$4M
Undisclosed Investor(s)
PIPE
Apr 2020
$4.5M
Undisclosed Investor(s)
PIPE
Dec 2019
$4.75M
Undisclosed Investor(s)
PIPE
Feb 2019
$7.5M
Undisclosed Investor(s)
PIPE
Nov 2017
$2.5M
Undisclosed Investor(s)
PIPE
May 2017
$2.69M
Undisclosed Investor(s)
PIPE
Aug 2016
$5.9M
Undisclosed Investor(s)
Undisclosed Round
Oct 2014
$12M
Docor International Management, Pontifax, General Electric, Shanghai Fosun Pharmaceutical
Undisclosed Round
Mar 2011
$9.88M
Undisclosed Investor(s)
Public Offering / Exit
MNAEvent
Sep 2025
Undisclosed
POEvent
May 2018
Undisclosed
POEvent
Mar 2015
Undisclosed
Mergers & Acquisitions
MNAEvent
Mar 2024
Undisclosed
Check-Cap Lifecycle
Cumulative Funding Raised Over Time
$4.0MApr 2020
$8.5MApr 2020
$14.4MAug 2016
$19.1MDec 2019
$26.6MFeb 2019
$26.9MJan 2022
$62.0MJun 2021
$71.8MMar 2011
$81.8MMar 2022
$84.5MMay 2017
$87.5MMay 2020
$90.0MNov 2017
$102.0MOct 2014
All Events
PIPE
Mar 2022
$10M
Undisclosed Investor(s)
PIPE
Jan 2022
$300K
Intempo Ventures
PIPE
Jun 2021
$35M
Undisclosed Investor(s)
PIPE
May 2020
$3M
Undisclosed Investor(s)
PIPE
Apr 2020
$4M
Undisclosed Investor(s)
PIPE
Apr 2020
$4.5M
Undisclosed Investor(s)
PIPE
Dec 2019
$4.75M
Undisclosed Investor(s)
PIPE
Feb 2019
$7.5M
Undisclosed Investor(s)
PIPE
Nov 2017
$2.5M
Undisclosed Investor(s)
PIPE
May 2017
$2.69M
Undisclosed Investor(s)
PIPE
Aug 2016
$5.9M
Undisclosed Investor(s)
Undisclosed Round
Oct 2014
$12M
Docor International Management, Pontifax, General Electric, Shanghai Fosun Pharmaceutical
Undisclosed Round
Mar 2011
$9.88M
Undisclosed Investor(s)
MNAEvent
Sep 2025
Undisclosed
POEvent
May 2018
Undisclosed
POEvent
Mar 2015
Undisclosed
MNAEvent
Mar 2024
Undisclosed
Check-Cap News
72 articles
growth-positive
MBody AI and Check-Cap Enter into Definitive Merger Agreement
Check-Cap Ltd. and MBody AI have announced a definitive merger agreement to create a combined company focused on embodied AI for the autonomous workforce. The merger, pending approval from Check-Cap shareholders, aims to leverage MBody AIs expertise in AI to expand into various industries such as hospitality, warehousing, and healthcare. The combined company will retain Check-Caps legacy assets, including patents and proprietary medical equipment, and will be renamed MBody AI Ltd. The merger is seen as a strategic move to enter a high-growth industry and capitalize on the expanding embodied AI market.
Acquired-by
growth-negative
Check-Cap claims BMO’s Chris Taves Illegally Attacks Israeli NASDAQ-Listed Company During Wartime
Check-Cap Ltd., a clinical-stage medical diagnostics company, has publicly condemned MediPharm Labs Corp. and its Chairman, Chris Taves, for issuing false and defamatory statements about Check-Cap. The company accuses Taves of exploiting his position at BMO Capital Markets to manipulate Check-Caps stock price by spreading misleading information during a sensitive time for Israeli companies. Check-Cap demands a retraction and apology from MediPharm Labs and Taves, asserting that their actions violate U.S. securities laws. Check-Cap is committed to defending its reputation and rights against these unethical attacks.
growth-negative
Apollo Technology Capital Corporation Poses Questions That MediPharm Shareholders Should Ask on Management's Conference Call with Shareholders
MediPharm Labs Corp. is facing significant challenges, with its stock value having plummeted by 99%, costing shareholders nearly $1 billion. Apollo Capital, a major shareholder, is pushing for changes in the companys board by nominating six new directors. The management team, led by CEO David Pidduck, has been criticized for poor operational strategies, lack of transparency, and excessive compensation despite the companys poor performance. The upcoming 2025 Annual Meeting on June 16 will be crucial as shareholders are urged to vote for a change in leadership. The company is also dealing with financial instability and accusations of misleading accounting practices.
Management Changes
growth-negative
Apollo Technology Capital Corporation to Nominate Six Highly Qualified Directors to MediPharm Labs' Board of Directors Following Years of Shareholder Value Destruction
Apollo Technology Capital Corporation, a significant shareholder of MediPharm Labs Corp., has filed a dissident information proxy circular to nominate six new directors to MediPharms Board. Apollo criticizes the current Board for the companys poor performance, reckless acquisitions, and excessive compensation, which have led to a significant decline in shareholder value. Apollos nominees bring extensive experience in turnaround strategies and the cannabis industry, aiming to restore value for shareholders. The Annual Meeting to vote on these changes is scheduled for June 10, 2025.
Management Changes
growth-negative
Check-Cap Leads 3 US Penny Stocks To Monitor
Check-Cap Ltd. is a clinical-stage medical diagnostics company focused on developing a capsule-based screening technology for colon diagnostics. Despite being pre-revenue and having a small market cap of $4.53 million, the company maintains financial stability with no debt and a sufficient cash runway. Recent management changes include David Lontini taking an active role as Chairman. The company is in the clinical trial stage and has not faced significant shareholder dilution. The article highlights the potential of penny stocks like Check-Cap in a market downturn, despite their inherent risks.
Product StageManagement Changes
growth-positive
Nobul AI Corp and Check-Cap Ltd Enter into Definitive Business Combination Agreement
Nobul AI Corp. and Check-Cap Ltd. have announced a definitive Business Combination Agreement, under which Nobul shareholders will become the majority holders of the combined company. The combined company, which will be headquartered in Toronto, Canada, will focus on an AI-driven fintech marketplace and buying and AI-enabling traditional companies. The combined company will apply for listing on the NASDAQ and TSX. The executive team of Nobul will serve as the executive team of the combined company. The proposed transaction has been approved by the board of directors of both companies.
AcquisitionPublic TradingManagement Changes
Growth-Positive
SYMETRYX COMMENTS ON SUCCESSFUL CAMPAIGN AT CHECK-CAP LTD
Symetryx Corporation, a Canadian venture company, has announced that shareholders of Check-Cap Ltd. voted in favor of all director nominees proposed by Symetryx at the Annual General Meeting held on December 18, 2023. The shareholders also voted against the proposed merger with Keystone Dental. Symetryx, as one of the largest shareholders of Check-Cap, expressed gratitude for the support and encouraged the newly elected board to find a more suitable merger candidate. Check-Cap is an Israel-based company known for its patented C-Scan technology that helps prevent colorectal cancer.
Management ChangesAcquisition
growth-positive
SYMETRYX COMMENTS ON SUCCESSFUL CAMPAIGN AT CHECK-CAP LTD
Symetryx Corporation, a Canadian venture company, announced that the shareholders of Check-Cap Ltd. voted overwhelmingly to elect all director nominees proposed by Symetryx at the Annual General Meeting on December 18th, 2023. The shareholders also voted against the proposed merger with Keystone Dental. Symetryx, as one of the largest shareholders, expressed gratitude for the support and emphasized the potential upside for Check-Cap. They encouraged the new board to find a more suitable merger candidate. Check-Cap, based in Israel, has developed a breakthrough technology, C-Scan, for colorectal cancer prevention. The technology has received European regulatory clearance and FDA Breakthrough Device Designation. Symetryx looks forward to a brighter future for Check-Cap and its shareholders.
Acquired-by
growth-positive
Check-Cap Board of Directors Issues Letter to Shareholders
Check-Cap, Ltd. has won a legal motion filed by Symetryx in Israeli court, with the court rejecting all claims raised by Symetryx. The claims were related to a personal interest or conflict of interest of Check Cap’s Board of Directors in the Keystone business combination. The court ordered Symetryx to pay Check-Cap’s expenses incurred in connection with the legal proceeding. Check-Caps Board of Directors conducted a robust independent process with Ladenburg, a reputable investment bank, and selected Keystone as the best merger partner. ISS, the leading independent research company, also evaluated and confirmed the process and independence of the Check-Cap Board of Directors.
CustomersPartners
growth-negative
CHECK- CAP BOARD MEMBER'S STATEMENT ON THE STAND SUGGESTS A POTENTIAL CONFLICT OF INTEREST WITH KEYSTONE DENTAL
Symetryx is urging shareholders of Check-Cap Ltd. to vote against a merger with Keystone Dental and instead vote for Symetryxs independent board nominees. A potential conflict of interest between Uri Geiger, Chairman of Keystone Dental, and Yuval Yanai, a Check-Cap director, was revealed during a court hearing. The U.S. FDA has received over 500 complaints in 2023 about Keystone Dentals medical defects and deficiencies. Symetryx believes the merger does not provide maximum value for shareholders and could negatively impact their investment.
PartnersManagement Changes
growth-negative
CHECK- CAP BOARD MEMBER'S STATEMENT ON THE STAND SUGGESTS A POTENTIAL CONFLICT OF INTEREST WITH KEYSTONE DENTAL
Symetryx is urging Check-Cap Ltd. shareholders to vote against the proposed merger with Keystone Dental, citing potential conflicts of interest and concerns over Keystones business practices. A court hearing revealed a potential conflict involving Keystones Chairman, Uri Geiger, and Check-Cap director, Yuval Yanai, who was offered a board seat post-merger. Both have ties to Minerva Surgical and Exalenz Bioscience, raising questions about the mergers approval process. Additionally, the FDAs MAUDE database has logged over 500 complaints against Keystone Dental in 2023, highlighting medical defects and deficiencies. These issues could harm Keystones financial condition and negatively impact Check-Caps shareholders. The vote deadline is December 14, 2023.
Acquired-by
growth-negative
CITING THE MANY FDA ADVERSE EFFECTS TO KEYSTONE DENTAL - CHECK-CAP FOUNDER STRONGLY RECOMMENDS VOTING AGAINST THE KEYSTONE DENTAL MERGER ALSO RECOMMENDS VOTING FOR THE SYMETRYX BOARD NOMINEES
Symetryx has urged its fellow Check-Cap Ltd. shareholders to vote against the Keystone Dental and for the Symetryx slate of highly qualified and independent director nominees. This comes after Keystone Dental received a deficiency letter from the FDA regarding its Paltop Short Implants, which may require a new filing submission and could potentially harm Keystones business. Symetryx believes the transaction with Keystone Dental does not provide maximum value for shareholders and has engaged Mackenzie Partners, Inc. as an advisor in this matter.
InvestmentManagement Changes
growth-negative
CITING THE MANY FDA ADVERSE EFFECTS TO KEYSTONE DENTAL - CHECK-CAP FOUNDER STRONGLY RECOMMENDS VOTING AGAINST THE KEYSTONE DENTAL MERGER ALSO RECOMMENDS VOTING FOR THE SYMETRYX BOARD NOMINEES
Symetryx is urging Check-Cap Ltd. shareholders to vote against a proposed transaction with Keystone Dental, citing concerns over Keystones recent FDA deficiency letter regarding its Paltop Short Implants. The FDA has requested additional information, and Keystone may face enforcement actions if a new filing is deemed necessary. Symetryx argues that the transaction does not maximize shareholder value and advocates for a new board of directors to better realize investment potential. The article highlights the potential negative impact on Keystones business and the importance of the upcoming shareholder vote.
Growth-Positive
CHECK-CAP FOUNDER STRONGLY RECOMMENDS VOTING AGAINST THE KEYSTONE DENTAL MERGER AND FOR THE SYMETRYX BOARD OF DIRECTORS NOMINEES
Symetryx Corporation is urging shareholders of Check-Cap Ltd. to vote against the Keystone Dental transaction, arguing that it does not provide maximum value for shareholders. Symetryx also encourages shareholders to support its slate of independent director nominees. The company has engaged Mackenzie Partners, Inc. as an advisor in this matter. This follows a news release by Yoav Kimchy, the Founder and former Chief Technology Officer of Check-Cap, who stated that the value of the Intellectual Property of Check-Cap was disregarded in the valuation of the Keystone Dental transaction.
Partners
growth-negative
CHECK-CAP FOUNDER STRONGLY RECOMMENDS VOTING AGAINST THE KEYSTONE DENTAL MERGER AND FOR THE SYMETRYX BOARD OF DIRECTORS NOMINEES
Symetryx Corporation is urging fellow shareholders of Check-Cap Ltd. to vote against a proposed transaction with Keystone Dental, arguing that the deal undervalues Check-Caps intellectual property. Symetryx advocates for a new slate of independent directors to maximize shareholder value. The company has engaged Mackenzie Partners, Inc. as an advisor and is actively seeking shareholder support to reject the Keystone transaction. Symetryxs stance is based on their analysis of publicly available information, although they acknowledge that their assumptions may not be accurate. The announcement emphasizes the importance of shareholder action to protect their investment.
growth-positive
Keystone Dental Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
Keystone Dental Group reported an 18.9% increase in Q3 revenue year-over-year, reaching $16.8 million, with $11.9 million generated in the U.S. This growth is attributed to increased sales of dental implants and Osteon product groups. The company launched the GENESIS ACTIVE™ Implant System and Nexus Connect, both innovative solutions in dental implant technology. Keystone Dental also received a patent for the Nexus IOS solution, enhancing its digital dentistry capabilities. Additionally, Greg Minzenmayer was appointed as Vice President & Global General Manager for Osteon Medical, a subsidiary acquired in 2021. Check-Cap shareholders are set to vote on a proposed Business Combination Agreement with Keystone Dental on December 18, 2023.
Acquisition
growth-negative
Symetryx Today Issues Open Letter to Shareholders In Regard to the Upcoming Annual General Meeting
Symetryx, a 5.6% shareholder of Check-Cap Ltd., has issued a letter urging fellow shareholders to vote against the proposed merger with Keystone Dental. Symetryx raises concerns about the unrealistic valuation of Keystone Dental and the high cash burn by Check-Caps board and management. They recommend voting for their slate of director candidates to ensure better accountability and find a more suitable merger partner. The letter highlights the potential dilution of shareholder value if the Keystone transaction proceeds. The Check-Cap Annual General Meeting is scheduled for December 18th, 2023, where these issues will be addressed.
Acquired-by
growth-positive
Keystone Dental Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
Keystone Dental Group has reported an 18.9% YoY increase in Q3 revenue to $16.8M, including $11.9M from the US. The company has also announced the launch of several new products, including the GENESIS ACTIVE™ Implant System and Nexus Connect. In addition, Keystone Dental has appointed Greg Minzenmayer as Vice President & Global General Manager for Osteon Medical, a subsidiary of Keystone Dental. The company is also set to vote on a proposed Business Combination Agreement with Check-Cap at an Annual General Meeting on December 18th, 2023.
CustomersPartnersAcquisitionManagement Changes
growth-negative
Symetryx Today Issues Open Letter to Shareholders In Regard to the Upcoming Annual General Meeting
Symetryx, a holder of 5.6% of Check-Cap Ltd. shares, has issued an open letter to shareholders expressing its concerns about the proposed merger with Keystone Dental. Symetryx criticizes the valuation of Keystone Dental and the cash burn by Check-Caps board and management. It urges shareholders to vote against the merger and the Check-Cap board nominees, and instead vote for its own slate of director candidates. The letter also raises concerns about the lack of financial transparency and the potential for the merger to be value-destructive and dilutive.
CustomersPartnersAcquisitionManagement Changes
growth-positive
Check-Cap Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
Check-Cap Ltd. has announced its financial results for the third quarter and nine months ending September 30, 2023. The company has also provided an update on its proposed Business Combination Agreement with Keystone Dental. The agreement, announced in August 2023, will see Keystone Dentals stockholders become the majority holders of the combined company. The combined company will focus on the commercial execution and market development of Keystone Dentals portfolio of implants and other tooth replacement solutions. The company has scheduled a shareholders meeting for December 18, 2023, to vote on the agreement.
PartnersManagement ChangesLayoffs
growth-positive
Keystone Dental Announces Launch of the GENESIS ACTIVE™ Dental Implant System: Revolutionizing Dental Implantology
Keystone Dental Group has announced the commercial launch of its GENESIS ACTIVE Implant System, a surgical solution for dental implant placement and restoration. The system is backed by over a decade of research and development and is expected to redefine the standard of implant procedures. In August 2023, Keystone Dental and Check-Cap Ltd. announced a definitive Business Combination Agreement under which the stockholders of Keystone Dental will become the majority holders of the combined company. The combined company will trade on the NASDAQ under the symbol “KSD.”
CustomersPartnersAcquisition
growth-positive
Keystone Dental Announces Launch of the GENESIS ACTIVE™ Dental Implant System: Revolutionizing Dental Implantology
Keystone Dental Holdings has announced the commercial launch of its GENESIS ACTIVE Implant System, a cutting-edge solution in dental implant technology. This new system is designed to revolutionize implant placement and restoration by offering a comprehensive portfolio of innovative solutions. The GENESIS ACTIVE Implant System includes features such as AnaTite™, BioSpark™, and Digital Guidance Sleeve, which enhance the efficiency and effectiveness of dental procedures. This launch marks a significant step forward in dental implantology, emphasizing Keystone Dentals commitment to innovation and patient care. The system is backed by over a decade of research and development, aiming to set a new standard in the industry.
growth-positive
Keystone Dental Announces Market Launch of Nexus Connect, the First A.I. Enabled Intraoral Implant-Scan Analyzer for the Nexus iOS Full-Arch Solution
Keystone Dental Group has announced the launch of Nexus Connect, a software system that uses machine learning to analyze implant scans. The software provides real-time results at the chairside, allowing clinicians to assess the quality and accuracy of their digital implant scans. The system was developed over a two-year period and is expected to bring a paradigm shift in digital implant dentistry. Keystone Dental acquired Osteon Medical in September 2021, which manufactures the prosthetic device used in conjunction with Nexus Connect. In August 2023, Keystone Dental and Check-Cap Ltd. entered into a Business Combination Agreement, with Keystone Dentals stockholders becoming the majority holders of the combined company.
AcquisitionPartners
growth-positive
Check-Cap Issues Letter to Shareholders Regarding Proposed Merger with Keystone Dental Holdings
Check-Cap Ltd. has announced a definitive Business Combination Agreement to merge with Keystone Dental Holdings. The merger is seen as a strategic move to create long-term value for Check-Caps shareholders. Keystone Dental, a global commercial-stage medical technology company, was chosen after an extensive bidding process due to its strong business prospects, experienced management, and limited regulatory risk. The merger values Check-Cap at $39.7 million, subject to adjustments. Keystone Dental operates in large underpenetrated markets with strong growth potential and generated significant revenue in 2022 and the first half of 2023. The merger is expected to provide Check-Cap shareholders with opportunities for growth in the combined company. An extraordinary general meeting of shareholders will be convened for approval of the merger.
Acquired-by
Check-Cap Issues Letter to Shareholders Regarding Proposed Merger with Keystone Dental Holdings
Keystone Dental Group Granted Patent from USPTO for Nexus IOS Solution
growth-positive
Keystone Dental Group Granted Patent from USPTO for Nexus IOS Solution
Keystone Dental Group has been granted a U.S. patent for its Nexus IOS Scan Gauge technology, which enhances the process of dental implant scanning. This patent strengthens Keystones market position and patent portfolio, which already includes over 75 claims globally. The company anticipates further patent approvals in other countries. Additionally, Keystone Dental has entered a Business Combination Agreement with Check-Cap Ltd., which will result in a public company trading on NASDAQ under the symbol KSD. This move is expected to enhance Keystones market development and commercial execution capabilities. The executive team of Keystone Dental will lead the combined company, with Melker Nilsson as CEO.
Public TradingAcquisition
Neutral
SYMETRYX OPPOSES CHEK CAP/KEYSTONE MERGER, WILL EVALUATE OPTIONS TO STOP TRANSACTION
Symetryx Corporation has announced its opposition to the proposed merger between Check-Cap Ltd. and Keystone Dental Holdings, Inc., stating it does not believe the transaction is in the best interest of Check-Cap shareholders. Symetryx has expressed concerns over Check-Caps financial health, noting the companys continued cash burn and the vague terms of the Business Combination Agreement with Keystone Dental. The announcement follows Symetryxs review of the SEC filings related to the merger.
Partners
growth-positive
בגלל החקיקה המשפטית: חברת צ'ק קאפ כבר לא תהיה ישראלית
Israeli company Check-Cap, which is traded on NASDAQ with a value of $18 million, has announced that it is merging with Keystone Dental, a company in the field of dental implants and other dental products. Following the deal, the merged company will trade at a value of $265 million. The existing shareholders of Keystone will hold 85% of the merged company. Keystone, which operates from California with a development center in Caesarea, was established in the US and had $400 million invested in it. However, after running into difficulties, it was acquired in 2018 for only $15 million by ExcelMed. In 2021, Keystone raised $25 million from the American hedge fund Nanthahala, with the participation of existing investors ExcelMed and Migdal Insurance.
AcquisitionManagement Changes
growth-positive
Keystone Dental Holdings and Check-Cap Ltd Enter into Definitive Business Combination Agreement
Keystone Dental Holdings, Inc. and Check-Cap Ltd. have announced a definitive Business Combination Agreement. The stockholders of Keystone Dental will become the majority holders of the combined company, which will be publicly traded on the NASDAQ under the ticker “KSD”. The business combination is expected to advance the commercial execution and market development of Keystone Dental’s portfolio of implants, arches and other tooth replacement solutions. The combined company will be led by Keystone’s CEO, Melker Nilsson. The business combination is subject to the approval of Check-Cap shareholders at a special meeting expected to occur in Q4 2023.
AcquisitionPublic Trading
growth-negative
Check-Cap Reports Second Quarter 2023 Financial Results
Check-Cap Ltd. has announced its financial results for Q2 and H1 2023. The companys R&D expenses increased by $1.0 million compared to the same period in 2022, primarily due to termination of clinical studies and operations, and termination expenses for employees. General and administrative expenses also increased by $0.3 million. The company recorded an impairment loss of $1.4 million and an operating loss of $7.4 million for Q2 2023. Net loss was $6.9 million for Q2 2023, compared to $4.8 million for the same period in 2022. Cash and cash equivalents, restricted cash and short-term bank deposits as of June 30, 2023 were $32.4 million.
Layoffs
growth-positive
SYMETRYX CORP INCREASES NON-BINDING OFFER TO ACQUIRE CHECK-CAP TO $4.60 PER SHARE
Symetryx Corporation has increased its non-binding proposal to acquire common shares of Check-Cap LTD from $4.35 to $4.60 per share. Symetryx has been buying Check common shares in the market and has increased its position. The company has requested to begin due diligence and communication with the Check Board of Directors. If the Check Board does not engage, Symetryx may consider commencing a tender offer directly to Check shareholders. The proposal is contingent upon several conditions including engagement with the Check Board, satisfactory due diligence and financing arrangements, and approval of Check shareholders.
Acquisition
growth-negative
Check-Cap Announces Review of Strategic Alternatives and Reduction in Workforce
Check-Cap Ltd. is exploring strategic alternatives to maximize stockholder value, including the sale of all or part of the company, licensing, merger, or reverse merger. The companys most recent efficacy results did not meet the goal for the U.S. pivotal study, leading the board of directors to pursue strategic options. As a result, the company plans to reduce its workforce by approximately 90% and discontinue the calibration studies. Check-Cap is a clinical stage medical diagnostics company focused on redefining colorectal cancer screening through its C-Scan technology.
Management ChangesLayoffs
growth-negative
חברת צ'ק-קאפ קרבה לסוף דרכה - Techtime - חדשות אלקטרוניקה והייטק
Check-Cap, a company that developed an ingestible X-ray capsule for the detection of pre-cancerous polyps in the colon, announced it will not continue its clinical trial in the US and has laid off about 90% of its employees. The company will now try to sell its intellectual property to maximize value for shareholders. This comes after the failure of the last clinical trial conducted in Israel and the US. The company has hired the consulting services of American investment bank Ladenburg Thalmann & Co to examine a range of options, including selling the company or part of it, granting licenses, merging or reverse merging.
Layoffs
growth-negative
Check-Cap Reports First Quarter 2023 Financial Results
Check-Cap Ltd., a clinical stage medical diagnostics company, announced its Q1 2023 financial results. The company reported a decrease in research and development expenses and general and administrative expenses compared to the same period in 2022. However, the company also reported a net loss of $4.4 million for Q1 2023. Additionally, the company announced that the initiation of the powered portion of the U.S. pivotal study was temporarily postponed due to efficacy results of its calibration studies not meeting internal goals. The company is now working with the FDA to amend the U.S. pivotal study protocol.
Management ChangesLayoffs
growth-negative
Check-Cap Reports Fourth Quarter and Full Year 2022 Financial Results
Check-Cap Ltd., a clinical stage medical diagnostics company, announced its financial results for Q4 and full year 2022. The company reported a net loss of $3.7 million for Q4 2022, compared to a net loss of $5.5 million for the same period in 2021. For the full year, the net loss was $19.1 million, compared to $17.2 million in 2021. The company also announced that it has postponed the initiation of the powered portion of the U.S. pivotal study due to current efficacy results not meeting its goal. As a result, the company is implementing a cost reduction plan and conducting additional clinical data analysis.
InvestmentManagement Changes
growth-negative
Why Are Check-Cap Shares Plummeting Today?
Check-Cap Ltd has announced that the current efficacy results from its calibration studies do not meet the goal to proceed to the powered portion of the U.S. pivotal study. The company had initiated the first part of the pivotal U.S. study of C-Scan in May 2022. As a result, the initiation of the powered portion of the U.S. pivotal study that was expected in mid-2023 is temporarily postponed. The company plans to continue conducting its calibration studies, albeit slower, and is implementing a cost reduction plan to extend its cash runway. Following the announcement, Check-Caps shares fell by 44.10%.
Management ChangesLayoffs
growth-negative
Check-Cap Issues an Update to Shareholders
Check-Cap Ltd., a medical diagnostics company, has announced that the current efficacy results of its C-Scan program do not meet their goal, leading to the postponement of the powered portion of the U.S. pivotal study. The company plans to conduct additional clinical data analysis, make amendments to the study protocol, and approach the FDA for approval. They will also continue conducting calibration studies at a slower pace and implement a cost reduction plan to extend their cash runway. Check-Cap aims to redefine colorectal cancer screening through its patient-friendly C-Scan test. The test uses an ultra-low dose X-ray capsule and proprietary software to generate a 3D map of the colon lining. A positive C-Scan result should be followed by colonoscopy.
InvestmentManagement Changes
growth-positive
צ'ק-קאפ הקימה קו ייצור סדרתי של גלולות רנטגן - Techtime - חדשות אלקטרוניקה והייטק
Check-Cap, an Israeli company, has established a production line for its X-ray capsule, designed to detect pre-cancerous polyps in the colon. The production line is located at the companys headquarters in Isfiya, Israel. The company is currently conducting a pivotal clinical trial in the United States with about 1,000 participants. Despite delays in the clinical trial, CEO Alex Ovadia believes the companys competitive advantage remains intact due to the combination of sensitivity, prevalence, and willingness to test.
Expand
growth-negative
Check-Cap Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
Check-Cap Ltd., a clinical stage medical diagnostics company, has announced its financial results for the third quarter and nine months ended September 30, 2022. The company reported a net loss of $4.7 million for the third quarter and $15.4 million for the nine months. Research and development expenses increased due to increased employee head count and clinical related expenses. The company also reported on its efforts to expand the number of U.S. sites for its C-Scan study and increase patient enrollment. Additionally, Check-Cap effected a reverse share split of the companys ordinary shares at a ratio of 1-for-20 on November 23, 2022.
InvestmentExpand
Growth-Positive
Check-Cap Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
Check-Cap Ltd., a clinical stage medical diagnostics company, has announced its financial results for Q2 and the first half of 2022. The company has initiated the first part of the U.S. pivotal study of C-Scan, a patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer. The companys shareholders approved a reverse share split of the companys ordinary shares. The company also announced that it has sufficient capital to fund its ongoing operations and plans into the second quarter of 2024.
Management ChangesInvestment
growth-negative
Check-Cap Ltd. (NASDAQ: CHEK) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement
Check-Cap Ltd. announces that it has received a letter from Nasdaq stating that it is eligible for an additional 180-day period to regain compliance with the minimum bid price per share requirement. The company was first notified of its failure to maintain the minimum bid price in December 2021 and did not regain compliance during the initial 180-day period. If the bid price closes at or above $1 per share for 10 consecutive trading days before December 19, 2022, the company will regain compliance.
Public Trading
growth-positive
Check-Cap Announces Initiation of the U.S. Pivotal Trial
Check-Cap Ltd. has initiated its U.S. pivotal trial of C-Scan®, a patient-friendly screening test for colorectal cancer. The trial will be conducted at Mayo Clinic in Rochester, Minnesota, and has obtained Institutional Review Board approval. The trial aims to demonstrate the potential of C-Scan to detect colorectal polyps before they turn into cancer. Check-Cap plans to complete the calibration portion of the trial and begin the second statistically powered portion in Q4 2022. The company believes C-Scan has the potential to improve colon cancer screening by reaching those who are deterred by colonoscopy. Colorectal cancer is the third most commonly diagnosed cancer globally, and Check-Caps technology aims to enable early intervention and cancer prevention.
Customers
growth-positive
Check-Cap Announces FDA Approval of Amended IDE Application for Pivotal Study of C-Scan
Check-Cap Ltd. has received approval from the U.S. Food and Drug Administration (FDA) for its amended Investigational Device Exemption (IDE) application, enabling initiation of the U.S. pivotal study. The study consists of two parts, with the first part focused on calibration and the second part comparing the performance of C-Scan to traditional colonoscopy. Check-Cap aims to redefine colorectal cancer screening with its patient-friendly preparation-free screening test.
Investment
growth-positive
Check-Cap Issues Letter to Shareholders
Check-Cap Ltd., a medical diagnostics company, has issued a letter to its shareholders and the investment community providing updates on its C-Scan program and recapping its progress in 2021. The company received approval from the FDA for its Investigational Device Exemption application and plans to initiate a two-part pivotal study in the U.S. The study will focus on device calibration, enhancement of algorithms, and comparison of C-Scan to traditional colonoscopy. Check-Cap has also expanded its manufacturing capacity, strengthened its clinical team, and obtained patents for its technology. The company raised net proceeds of $31.8 million in 2021 and has a cash balance to fund operations into 2023. Check-Cap aims to address the low colorectal cancer screening rates by providing a patient-friendly screening option.
InvestmentManagement Changes
growth-positive
Check-Cap Announces Expansion of Manufacturing Capacity and Production Line to Support U.S. Pivotal Study Initiation
Check-Cap Ltd., a medical diagnostics company, has announced the expansion of its manufacturing capacity and on-premise production line for C-Scan, a patient-friendly screening test for colorectal cancer. The expansion is intended to support the companys upcoming U.S. pivotal study. Check-Cap aims to redefine colorectal cancer screening and increase screening adherence worldwide. C-Scan uses a capsule-based screening technology that requires no bowel preparation and generates a 3D map of the colon. The company is focused on optimizing C-Scans functionality and patient experience through additional clinical data collection in Israel. Check-Cap plans to initiate the U.S. pivotal study by the end of March 2022.
Expand
growth-positive
Check-Cap Ltd. Announces $35 Million Registered Direct Offering
Check-Cap Ltd. has entered into definitive agreements with several institutional and accredited investors for a registered direct offering of its ordinary shares and short-term warrants. The offering is expected to generate approximately $35 million in gross proceeds for Check-Cap. The company plans to use the net proceeds to advance the clinical development of C-Scan®, its patient-friendly screening test for colorectal cancer, and for general corporate purposes. The offering is subject to customary closing conditions and is expected to close on or about July 2, 2021. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
Investment
Check-Cap Doubles;FDA OKs Request to Study Polyp-Detection Test
growth-positive
Check-Cap Reports Third Quarter 2020 Financial Results and Corporate Highlights
Check-Cap Ltd., a clinical stage medical diagnostics company, has submitted an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for the pivotal study of C-Scan. The C-Scan is a patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer. The company also announced its financial results for Q3 2020, revealing that it had strengthened its balance sheet through gross proceeds of $9.6 million in a warrant exercise financing in July 2020. However, the COVID-19 pandemic has affected the companys ability to initiate its planned pivotal study and commence pilot sales in Israel and Europe.
Investment
growth-positive
צ'ק-קאפ הגישה ל-FDA בקשת היתר לבצע ניסוי רחב-היקף - Techtime - חדשות אלקטרוניקה והייטק
Check-Cap has submitted an application to the FDA for permission to conduct a pivotal clinical trial of its colon cancer screening device in the US. The company has already received approval for marketing in Europe and Israel. The trial in the US is the final step before the company can begin commercialization. Check-Caps device is a user-friendly alternative to colonoscopy, using a swallowed capsule with X-ray technology to detect pre-cancerous polyps in the colon. The low compliance rate for colonoscopy screening has led to late-stage diagnoses of colon cancer. The company plans to build a supporting manufacturing line and expand its clinical data system. The stock price of Check-Cap increased by 9% following the announcement.
InvestmentExpand
Growth-Positive
Check-Cap Reports Second Quarter 2020 Financial Results and Corporate Highlights
Check-Cap Ltd., a clinical stage medical diagnostics company, announced its financial results for the second quarter and six months ended June 30, 2020. The company raised $16.3 million in registered direct offerings and a private placement of ordinary shares in the first half of 2020, followed by $9.6 million in a warrant exercise financing in July 2020. The company believes that it has sufficient capital to fund its ongoing operations and plans for at least the next 12 months. The company also plans to submit an Investigational Device Exemption (IDE) to the FDA by the end of 2020, with initiation of a U.S. pivotal study of C-Scan planned for 2021.
Investment
growth-positive
Check-Cap Ltd. Announces $3.0 Million Registered Direct Offering
Check-Cap Ltd. has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 5,000,000 of the Companys ordinary shares, at a purchase price of $0.60 per share, in a registered direct offering. The offering is expected to close on or about May 13, 2020. The gross proceeds to Check-Cap from this offering are expected to be $3.0 million. The Company intends to use the net proceeds from the offering to advance the ongoing clinical development of C-Scan®, including preparations for the Companys U.S. pivotal study, and for general corporate purposes.
Investment
growth-positive
Check-Cap Ltd. Announces $4.5 Million Registered Direct Offering
Check-Cap Ltd. has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 7,500,001 of the Companys ordinary shares, at a purchase price of $0.60 per share, in a registered direct offering. The offering is expected to close on or about May 4, 2020. The gross proceeds to Check-Cap from this offering are expected to be approximately $4.5 million. The Company intends to use the net proceeds from the offering to advance the ongoing clinical development of C-Scan®, including preparations for the Companys U.S. pivotal study, and for general corporate purposes.
Investment
growth-positive
Check-Cap Ltd. Announces $4.0 Million Registered Direct Offering
Check-Cap Ltd. has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 6,666,669 of the Companys ordinary shares, at a purchase price of $0.60 per share, in a registered direct offering. The gross proceeds to Check-Cap from this offering are expected to be approximately $4.0 million. The company intends to use the net proceeds from the offering to advance the ongoing clinical development of C-Scan®, including preparations for the Companys U.S. pivotal study, and for general corporate purposes.
Investment
Growth-Negative
Check-Cap Provides Update on COVID-19 Pandemic Impact on Operational and Clinical Activities
Check-Cap Ltd., a clinical stage medical diagnostics company, has provided an update on the impact of the COVID-19 pandemic on its operations. The company has taken necessary precautions to ensure the safety of its employees, with the majority working remotely. Interactions between hospitals, healthcare professionals, employees, and clinical trial patients have been temporarily suspended. The pandemic has impacted the companys ability to conduct ongoing clinical studies, leading to the suspension of clinical trials until at least June 2020. The company is implementing cost reduction measures, including a 15% reduction in salaries and placing some employees on unpaid leave.
CustomersManagement ChangesLayoffs
growth-positive
Check-Cap reports positive results in US pilot study
Check-Cap Ltd., a company developing an ingestible scanning capsule-based system for the detection of precancerous polyps, has announced positive results from its pilot study in the US. The study evaluated the safety, usability, and subject compliance of the C-Scan System and showed no serious adverse events. The results were promising, and the company is now preparing for a US pivotal study in late 2020. Check-Cap aims to offer a patient-friendly screening option for detecting pre-cancerous polyps. The companys market cap is $14 million.
CustomersInvestment
growth-positive
Diagnostics co Check-Cap makes $4.75m private placement
Israeli medical diagnostics company Check-Cap has announced a $4.75 million investment through a private placement of shares. The proceeds will be used for general corporate and working capital purposes. Check-Cap is developing C-Scan System, a preparation-free ingestible scanning capsule-based system for the prevention of colorectal cancer. The company has a market cap of $14 million.
Investment
growth-positive
Check-Cap reports positive results on colon screening pill
Israeli medical diagnostics company Check-Cap has announced positive final results from its post-CE approval study on the C-Scan system, a capsule-based screening method for the prevention of colorectal cancer. The study showed that C-Scan correctly identified 76% of patients with polyps, compared to 29% for the commonly used FIT test. It also detected all 4 patients with larger polyps, while FIT only detected 1. Check-Cap plans to initiate a US pivotal study in 2020. The C-Scan system has received CE marking and approval from the Israeli Ministry of Health.
Customers
growth-positive
Mayo Clinic joins Check Cap pilot study
Check-Cap Ltd. has announced that Mayo Clinic is participating in the companys pilot study of its C-Scan system. The study aims to detect precancerous polyps for the prevention of colorectal cancer. Check-Cap also released its first quarter financials, reporting a net loss of $3.2 million. The increase in expenses was primarily due to ongoing clinical studies and preparations for the US pilot study.
Customers
growth-positive
Check-Cap Initiates U.S. Pilot Study of C-Scan® for Colorectal Cancer Screening
Check-Cap Ltd. has announced the initiation of its U.S. pilot study of the C-Scan® system, a preparation-free ingestible capsule for the prevention of colorectal cancer. The study has received approval from the U.S. Food and Drug Administration (FDA) and the first patients have already ingested the capsule. The pilot study aims to evaluate the safety, usability, and subject compliance of the C-Scan® system. Check-Cap believes that the patient-friendly scanning capsule has the potential to redefine the colorectal cancer screening landscape and decrease the overall incidence of the disease. Colorectal cancer is the second-leading cause of cancer death in the U.S., and the addition of a new screening option that does not require a bowel prep could increase screening rates.
Customers
growth-negative
Check-Cap raises $7.5m at 25% discount
Check-Cap, a company developing an x-ray imaging capsule for detecting polyps in the colon, has announced a $7.5 million financing round. The company is currently conducting clinical trials of its product in the US. The financing round was priced at a 25% discount on the market price before the announcement. Check-Caps share price has dropped 25% in Nasdaq pre-trading. The companys market cap was $18 million before the start of trading. Check-Cap plans to use the proceeds to further develop its product. Since its IPO in 2015, the companys share price has fallen 93% due to delays in clinical trials and unsatisfactory results in detecting tumors.
Investment
growth-positive
Check-Cap Receives Approval From the Israeli Ministry of Health to Initiate Commercial Sales in Israel of its C-Scan® System
Check-Cap Ltd. has received approval from the Israeli Ministry of Health to initiate commercial sales in Israel of its C-Scan system, a preparation-free, non-invasive colorectal cancer screening option. The approval reinforces the potential of the C-Scan system to increase CRC screening adherence and precancerous detection. The company plans to commercialize the C-Scan system in Israel in the second quarter of 2019, pending extension of the AMAR approval and subject to engaging with a strategic partner and sufficient available capital.
Customers
growth-positive
Check-Cap reports promising results on colonoscopy pill
Israeli medical diagnostics company Check-Cap Ltd. announced the results of a trial for its capsule product designed to replace a colonoscopy for colorectal cancer detection. The product has already been approved for marketing in Europe. The trial aimed to support its marketing. The share price of Check-Cap increased by 7% in preliminary trading. The trial involved 31 subjects and the pill detected polyps in 76% of cases and correctly detected the absence of polyps in 80% of cases. These results are an improvement over an earlier version of the product. Check-Cap CEO Alex Ovadia expressed excitement about the results and mentioned the companys plans for the future.
Customers
growth-negative
Check-Cap plunges after raising $17.5m in Nasdaq offering
Israeli medical device company Check-Cap announced it raised $17.5 million in a secondary offering at a 38% discount on its Nasdaq share price. Following the announcement, the companys share price plummeted 48%, reducing its market cap to $7 million. The offering included options that were initially in the money but became out of the money due to the share price decline. The funds raised are expected to support the completion of a crucial clinical trial for its polyp-detecting pill. The companys leading shareholders include Pontifax Venture Capital, Fosun Pharma, Quant Global Capital Advisors, Sabby Management, and Armistice Capital. The CEO is Alex Ovadia.
Investment
growth-positive
Check-Cap Appoints Alex Ovadia as Chief Executive Officer
Check-Cap Ltd. has appointed Alex Ovadia as Chief Executive Officer. Ovadia brings more than 25 years of experience in global operations and complex projects. The company believes that Ovadias leadership capabilities will help drive the commercial acceptance of their C-Scan product for colorectal cancer screening. Check-Cap recently received CE Mark approval for their breakthrough product. Ovadia will focus on bridging the gap towards commercialization and achieving the companys mission.
Management Changes
growth-positive
Check-Cap Receives CE Mark Approval for C-Scan®
Check-Cap Ltd. has received CE Mark approval for its C-Scan system, an ingestible capsule for preparation-free colorectal cancer screening. The C-Scan system offers an alternative to current screening methods that require laxative preparation and invasive procedures. It utilizes an ingestible X-ray capsule and a wireless tracking system to generate structural information on the colon, allowing physicians to identify pre-cancerous polyps and abnormalities. This approval is a significant accomplishment for the company and validates the potential of C-Scan as a convenient and comfortable option for colon polyp identification. Check-Cap plans to commence European post-approval and U.S. pilot trials in the first half of 2018.
Customers
growth-positive
Check-Cap Ltd. Announces Closing of $2.5 Million Registered Direct Offering
Check-Cap Ltd. has announced the closing of its registered direct offering with certain institutional investors. The offering consisted of 2,272,640 ordinary shares at a purchase price of $1.10 per share. The company also issued unregistered warrants to purchase up to 1,704,480 ordinary shares. The gross proceeds from the offering were approximately $2.5 million, with the potential for up to approximately $4.6 million in total gross proceeds if the warrants are exercised in full. The ordinary shares were offered pursuant to a shelf registration statement. The warrants and ordinary shares underlying the warrants were offered and sold in a private placement. Check-Cap is a clinical-stage medical diagnostics company developing a capsule-based system for colorectal cancer screening.
Investment
growth-positive
Check-Cap Ltd. Announces Closing of $2.69 Million Financing
Check-Cap Ltd. has announced the closing of a definitive agreement with a single health-care focused institutional investor for the purchase of 1,349,500 ordinary shares at a price of $2.00 per share. The company also issued one-year warrants to purchase up to 1,349,500 of its ordinary shares. The company received gross proceeds of approximately $2.69 million at the close of the offering and could receive approximately $5.57 million if the warrants are exercised in full for cash. Rodman & Renshaw acted as the exclusive placement agent for this offering.
Investment
growth-positive
Check-Cap Ltd. Announces $5.9 Million Financing
Check-Cap Ltd. has entered into an agreement with a single health-care focused institutional investor for a registered direct placement of $5.9 million. The company intends to use the net proceeds from the offering to advance the ongoing clinical development of its preparation-free, less-invasive colorectal cancer screening system, and for general corporate purposes. The placement is expected to close on or before August 11, 2016.
Investment
growth-positive
Check-Cap raises $24m, including Nasdaq IPO
Check-Cap, a diagnostic capsule company, raised $12 million in an IPO on Nasdaq and $12 million in a private placement led by Fosun Pharma. The IPO was priced at $12 million with a company value of $92 million, lower than the expected $15 million with a company value of $100 million. The IPO was considered a success despite the lower price. Check-Caps influential shareholders include GE Healthcare and Fosun Pharma. The funds raised will be used to complete the companys clinical trial and potentially launch its product in Europe in 2016 and the US in 2017.
InvestmentPublic Trading
growth-positive
Check-Cap files to raise $15m on Nasdaq
Check-Cap, a biomedical company, is developing a pill for conducting an X-ray scan of the intestine. They have submitted a draft prospectus to raise $15 million on Nasdaq, with an expected company value of a little over $100 million. This would make Check-Cap the first biomedical company to conduct an offering on Nasdaq in 2015. The company has already received a $12 million investment led by Fosun Pharma, and other investors include GE Healthcare and Pontifax. The IPO is seen as a positive growth opportunity for Check-Cap.
InvestmentPublic Trading
growth-positive
Check-Cap raises $12m in private placement
Check-Cap, a company developing a pill that conducts an X-ray scan of the intestine, has raised $12 million in a private placement led by Fosun Pharma. The financing round is in the form of a line of credit, and the investors have the option to convert it into shares. Check-Cap is considering a Nasdaq public offering and hopes to obtain marketing authorization in Europe. This is Fosun Pharmas first investment in Israel since acquiring Alma Lasers in 2013.
InvestmentPublic Trading
Check-Cap Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 32 |
| Team members | 7 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 14 classification IDs that could be used for matching.
Check-Cap Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 100/100 |
| Missing | markets |
| BI Verification | Sharon Shapira |
| Registrar ID | 514259811 |
| Crunchbase | check-cap |
| Phone | +97248303401 |
| Creator | Rebecca Mack |
| Creator email | rebeccamack26@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-11-22T00:00:00.000Z |
| Created | 2014-06-18T00:00:00.000Z |
| Claimed | Yes |
| Status detail | Acquired by MBody AI on Sep, 2025 |